Stocksigma LogoStocksigma Logo

Bio Medica Laboratories Reports Deviations in IPO Proceeds Utilization for H1FY27

CARE Ratings flagged deviations in Bio Medica Laboratories' IPO proceeds utilization for the half-year ended 30th Sep'26

Bio Medica Laboratories Reports Deviations in IPO Proceeds Utilization for H1FY27

Bio Medica Laboratories Ltd · Others (Uncategorized) · 14 Nov 2026, 9:27 pm

Bio Medica Laboratories Reports Deviations in IPO Proceeds Utilization for H1FY27 CARE Ratings flagged deviations in Bio Medica Laboratories' IPO proceeds utilization for the half-year ended 30th Sep'26. The company utilized ₹22.77 crore out of ₹47.19 crore fresh issue proceeds. Key deviations include General Corporate Purpose spending of ₹9.09 crore against an allocated ₹7.05 crore, loan repayments of ₹6.54 crore versus ₹6.50 crore, and capex deployment of ₹2.21 crore including ₹0.1965 crore GST. The company will rectify deviations by transferring ₹2.2765 crore from internal accruals back to the Monitoring Account by 30th Nov'26.

Original exchange filing (PDF)

More announcements from Bio Medica Laboratories Ltd

All Bio Medica Laboratories Ltd announcements